| Literature DB >> 34221025 |
Rita Lih-Ying Shin1, Chien-Wei Lee2,3, Oscar Yuan-Jie Shen4, Hongtao Xu1, Oscar Kuang-Sheng Lee1,2,5,6.
Abstract
Bone regeneration is a complex and well-coordinated process that involves crosstalk between immune cells and resident cells in the injury site. Transplantation of mesenchymal stem cells (MSCs) is a promising strategy to enhance bone regeneration. Growing evidence suggests that macrophages have a significant impact on osteogenesis during bone regeneration. However, the precise mechanisms by which macrophage subtypes influence bone regeneration and how MSCs communicate with macrophages have not yet been fully elucidated. In this systematic literature review, we gathered evidence regarding the crosstalk between MSCs and macrophages during bone regeneration. According to the PRISMA protocol, we extracted literature from PubMed and Embase databases by using "mesenchymal stem cells" and "macrophages" and "bone regeneration" as keywords. Thirty-three studies were selected for this review. MSCs isolated from both bone marrow and adipose tissue and both primary macrophages and macrophage cell lines were used in the selected studies. In conclusion, anti-inflammatory macrophages (M2) have significantly more potential to strengthen bone regeneration compared with naïve (M0) and classically activated macrophages (M1). Transplantation of MSCs induced M1-to-M2 transition and transformed the skeletal microenvironment to facilitate bone regeneration in bone fracture and bone defect models. This review highlights the complexity between MSCs and macrophages, providing more insight into the polarized macrophage behavior in this evolving field of osteoimmunology. The results may serve as a useful reference for definite success in MSC-based therapy based on the critical interaction with macrophages.Entities:
Year: 2021 PMID: 34221025 PMCID: PMC8219422 DOI: 10.1155/2021/8835156
Source DB: PubMed Journal: Stem Cells Int Impact factor: 5.443
Figure 1Flow diagram of the systematic review on the crosstalk of MSCs and macrophages. A total of 437 studies were retrieved based on the search strategy mentioned in the methods. Nine records after duplicates were removed. 44 works of literature published more than 10 years were excluded. After reviewing the titles and abstracts, 50 records were removed because the studies were not primary studies. After reviewing the titles and abstracts, 301 records were removed because the studies did not match the selection criteria. Finally, 33 studies met the inclusion criteria and were selected for this systematic review.
Figure 2Study characteristics of the systematic review. (a) Categories of experiments. (b) Animal models of the in vivo studies. (c) The origin of the MSCs applied in studies. (d) The origin of macrophages applied in studies. (e) The proportion of biomaterials used in studies. (f) Published year of selected studies. Database searching and study identification in this review are till Jan of 2020.
Immunoregulatory potential of MSCs on macrophages in bone regeneration.
| Author | Cell source | Study type | Cell management | Immunoregulatory potential of MSCs on M | Proposed mechanisms |
|---|---|---|---|---|---|
| Tasso R 2013 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vitro & in vivo | In vitro: M | In vitro: the percentage of M2 M | PGE2 secreted from BMSCs activates the NF- |
| Seebach E 2014 | SD rats—BMSCs; SD rats—M | In vivo | BMSCs embedded in a fibrin carrier are implanted into femoral bone defects | BMSC composites attract proinflammatory M1 M | / |
| Tour G 2014 | Lewis GFP transgenic rat—BMSCs; SD rats—M | In vivo | BMSCs with HA-ECM are implanted into calvarial bone defects | M1 M | / |
| Lin T 2017 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vitro | M | CM from MSCNF- | NF- |
| Lin T 2017 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vitro | Preconditioned BMSCs with LPS plus TNF- | Preconditioned BMSCs modulate M1 M | Preconditioned BMSC-secreted PGE2 can be stimulated by TNF- |
| Saldana L 2017 | Human—BMSCs; THP-1—M | In vitro | BMSCs undergo osteogenic differentiation with the CM from the cocultures of BMSCs, M | 1,25D3 promotes the switching of cocultured M | / |
| Li T 2018 | SD rats—BMSCs; RAW 264.7—M | In vitro & in vivo | In vitro: Lap/M | In vitro: BMSCs reversed M1 M | Activation of the OSM pathway is likely involved in the enhanced osteogenesis by BMSCs |
| He Y 2019 | SD rats—BMSCs; RAW 264.7—M | In vitro | In vitro: CM from BMSCs seeded on Ti-SF/LL-37 is applied on M | In vitro: M2 phenotype switching of M | / |
| Wei F 2019 | Human—BMSCs; RAW 264.7—M | In vitro | LPS-induced M | The uptake of exosomes significantly decreases the M1 phenotypic marker of LPS-induced M | / |
BMSCs: bone marrow stem cells; Mφs: macrophages; CM: conditioned medium; PGE2: prostaglandin E2; NF-κB: nuclear factor-kappa B; GFP: green fluorescent protein; HA-ECM: hydroxyapatite-extracellular matrix; LPS: lipopolysaccharide; TNF-α: tumor necrosis factor-alpha; COX2: cyclooxygenase 2; 1,25D3: 1,25-dihydroxyvitamin D3; Lap: laponite; OSM: oncostatin M; Ti-SF: titanium-silk fibroin; SFNPs: silk fibroin nanoparticles.
Involvement of M1 macrophages in MSC osteogenic differentiation and bone regeneration.
| Author | Cell source | Study type | Cell management | Involvement of M | Proposed mechanisms |
|---|---|---|---|---|---|
| Tu B 2015 | Human—BMSCs; THP-1—M | In vitro | M | IL-23 secretion from proinflammatory M | M |
| Hirata E 2016 | Human—BMSCs; human—M | In vitro | Coculture of BMSCs and M | ALP activity is increased under the coculture of M | OSM from activated M |
| Shi M 2016 | Human—BMSCs; RAW 264.7—M | In vitro | BMSCs cultured in Cu-MSN/M | M | Cu-MSN/M |
| Lu LY 2017 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vitro | Coculture of BMSCs and polarized M | Polarized M | M1 M |
| Tang H 2017 | Human—ADSCs; THP-1—M | In vitro | 3D spheroid cocultures of M1 M | The osteogenic differentiation of ADSCs is inhibited by M1 M | N-cadherin-mediated cell-cell interactions between M1 M |
| Xue D 2018 | Human—BMSCs; RAW 264.7—M | In vitro | BMSCs undergo osteogenic differentiation added with the CM from GO/M | Coculture of GO and M | The proinflammatory environment induced by GO promote osteogenic differentiation of BMSCs through OSM and NF- |
| Wasnik S 2018 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vivo | Mice with the fracture at the midshaft receive a daily s.c. dose of 1,25(OH)2D | The suppression of fracture healing induced by 1,25(OH)2D is mediated by the inhibition of M1 M | / |
| Nathan K 2019 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vitro | Coculture of BMSCs and M1 M | Temporal modulation of M1-to-M2 polarization maximizes MSC matrix mineralization | / |
| Tang H 2019 | Human—ADSCs; THP-1—M | In vitro | M1 M | M1 M | M1 M |
| Y He 2019 | SD rats—BMSCs; RAW 264.7—M | In vitro | In vitro: CM from M | In vitro: osteogenic differentiation of BMSCs was enhanced by additional CM from M | / |
BMSCs: bone marrow stem cells; Mφs: macrophages; CNHs: carbon nanohorns; ALP: alkaline phosphatase; OSM: oncostatin M; STAT3: signal transducer and activator of transcription 3; Cu-MSNs: Cu-containing mesoporous silica nanospheres; CM: conditioned medium; COX2: cyclooxygenase 2; PGE2: prostaglandin E2; GO: graphene oxide; NF-κB: nuclear factor-kappa B.
Involvement of M2 macrophages in MSC osteogenic differentiation and bone regeneration.
| Author | Cell source | Study type | Cell management | Involvement of M | Proposed mechanisms |
|---|---|---|---|---|---|
| Gong L 2016 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vitro | Coculture of BMSCs and polarized M | M2 M | Proregenerative cytokines (TGF- |
| Chen Z 2017 | SD rats—BMSCs; RAW 264.7—M | In vitro | CM from nanopore structure/M | Osteogenesis of BMSCs is enhanced by the stimulation of the nanostructure/M | Osteogenic pathways (Wnt and BMP) of BMSCs are regulated by different nanopore-induced inflammatory environments |
| Zhang Y 2017 | Human—ADSCs; THP-1—M | In vitro | Direct and indirect coculture of ADSCs and polarized M | M2 M | M2 M |
| Tang H 2017 | Human—ADSCs; THP-1—M | In vitro | 3D spheroid cocultures of M2 M | The osteogenic differentiation of ADSCs was inhibited by M2 M | N-cadherin-mediated cell-cell interactions between M2 M |
| He XT 2018 | C57BL/6 mice—BMSCs; RAW 264.7—M | In vitro | BMSCs incubated with different CMs generated by unpolarized M | CM from M2 M | / |
| Wang J 2018 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vitro | BMSCs undergo osteogenic differentiation with NT/M | NT-30 induces more M2 M | / |
| Ma QL 2018 | Human—BMSCs; human—M | In vitro & in vivo | In vitro: osteogenic differentiation of BMSCs on different Ti surfaces in CM from M | In vitro: the NT surfaces and corresponding CM types together promote osteogenic gene expression in BMSCs, and osteoclast formation is likely promoted by factors (sRANKL, OPG, and M-CSF) secreted by BMSCs cultured in NT20-CM but suppressed in NT5-CM | NF- |
| Jin SS 2019 | Human—BMSCs; THP-1—M | In vitro & in vivo | In vitro: BMSCs are cultured with supernatants of M | In vitro: M2 M | HIMC intrinsically promotes M2 M |
| Sadowska JM 2019 | Human—BMSCs, human—SaOS-2; RAW 264.7—M | In vitro | LPS-stimulated M | The microenvironment created after culturing M | / |
| Tang H 2019 | Human—ADSCs; THP-1—M | In vitro | M | Both macrophage subtypes inhibit the osteogenic differentiation of ADMSCs on 3D PLGA/PCL scaffolds | M |
| Yang C 2019 | Wistar rats—BMSCs; RAW 264.7—M | In vitro | In vitro: BMSCs undergo osteogenesis under the CM collected from M | In vitro: LiCl promotes M2 polarization, and the better osteogenic differentiation driven by Ti+LiCl-stimulated CM was also observed | LiCl attenuated wear Ti particle-induced inflammation via the suppression of ERK and p38 phosphorylation |
| Zhu K 2019 | C57BL/6 mice—BMSCs; RAW 264.7—M | In vitro | In vitro: crocin-pretreated M | In vitro: crocin-pretreated M | M2 polarization promoted by crocin via the inhibition of p38 and c-Jun N-terminal kinase |
| Lin T 2019 | Balb/c mice—BMSCs; Balb/c mice—M | In vitro | Coculture of BMSCs (preconditioned or genetically modified IL-4-secreting BMSCs) and M | Both IL-4-secreting BMSCs and preconditioned BMSCs enhance osteogenesis during coculture but at different stages (preconditioned MSCs on day 3 and IL-4-secreting MSCs on day 7) | Enhanced osteogenesis at a later stage associated with the M1-to-M2 M |
| Wang C 2019 | NZW rabbits—BMSCs; RAW 264.7—M | In vitro | Osteogenic differentiation of BMSCs with the supernatants of CS- and Sr-CS-pretreated M | Extracts from M | / |
| Wendler S 2019 | C57BL/6 mice—BMSCs; C57BL/6 mice—M | In vitro & in vivo | In vitro: osteogenic differentiation of BMSCs treated with the CM from bone marrow cells and iloprost | Iloprost decreases the proinflammatory phase and enhances the anti-inflammatory phase to improve bone healing | Iloprost signaling leads to an increase of anti-inflammatory agent cAMP to suppress M1 |
| Wu RX 2019 | SD rats—BMSCs; SD rats—M | In vivo | Rat periodontal defects are implanted with ECM particles and gels | Gel-type bone ECM has a greater tendency toward M2 polarization showing a better healing tendency | / |
| Gao A 2020 | Human—BMSCs; THP-1—M | In vitro & in vivo | In vitro: BMSCs undergo osteogenic differentiation with M | In vitro: M | PI3K-Akt signaling, TLR signaling, NLR signaling, and TNF- |
BMSCs: bone marrow stem cells; Mφs: macrophages; LPS: lipopolysaccharides; TGF-β: transforming growth factor-beta; VEGF: vascular endothelial growth factor; IGF-1: insulin-like growth factor 1; CM: conditioned medium; BMP: bone morphogenetic protein; ADSCs: adipose-derived stem cells; IFN-γ: interferon-gamma; OSM: oncostatin M; NT: nanotube; Ti: titanium; sRANKL: soluble receptor activator of nuclear factor-kappa B ligand; OPG: osteoprotegerin; M-CSF: macrophage colony-stimulating factor; NF-κB: nuclear factor-kappa B; HIMC: hierarchical intrafibrillar mineralized collagen; CaPs: calcium phosphates; CDHA: calcium-deficient hydroxyapatite; PLGA/PCL: poly(lactic-co-glycolic) acid/polycaprolactone; Ti+LiCl: titanium+lithium chloride; Sr-CS: strontium-incorporated calcium silicate; cAMP: cyclic adenosine monophosphate; ECM: extracellular matrix; PEEK: polyetheretherketone; PI3K-Akt: phosphoinositide 3-kinase/protein kinase B; TLR: toll-like receptor; NLR: NOD-like receptor; TNF-α: tumor necrosis factor-alpha.
| Section and topic | No. | Quality criteria | Yes | No |
|---|---|---|---|---|
| Title/keywords/introduction | 1 | Were the study hypothesis/aim/objective being clearly described | ||
| Method | 2 | Were the experimental design for the study being well described | ||
| 3 | Were the method and materials being well described | |||
| 4 | Were the time points of data collection being clearly defined | |||
| 5 | Were the main outcome measurements being clearly defined | |||
| 6 | Were the experimental group being well compared with the control group | |||
| Discussion | 7 | Were the results being well described | ||
| 8 | Were the limitation of the article being discussed |
Wells and Littell [22].
| Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Quality score |
|---|---|---|---|---|---|---|---|---|---|
| Tasso et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Seebach et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Tour et al. | Yes | Yes | Yes | Yes | No | Yes | Yes | No | 6 |
| Tu et al. | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | 8 |
| Gong et al. | Yes | Yes | Yes | Yes | No | No | Yes | No | 5 |
| Hirata et al. | Yes | Yes | Yes | Yes | No | Yes | Yes | No | 6 |
| Shi et al. | Yes | Yes | Yes | Yes | Yes | No | Yes | No | 6 |
| Chen et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Lin et al. (Cytotherapy) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Lin et al. (Stem Cell Res Ther) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Lu et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Saldana et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Tang et al. (Tissue Cell) | Yes | Yes | No | Yes | No | Yes | Yes | No | 5 |
| Zhang et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| He et al. | Yes | Yes | Yes | Yes | Yes | Yes | No | No | 6 |
| Li et al. | No | Yes | Yes | Yes | Yes | Yes | Yes | No | 6 |
| Ma et al. | No | No | Yes | Yes | Yes | Yes | Yes | No | 5 |
| Wang et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Wasnik et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Xue et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| He et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Jin et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Lin et al. (Tissue Eng Part A) | No | Yes | Yes | Yes | Yes | Yes | Yes | No | 6 |
| Nathan et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Sadowska et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Tang et al. (J Tissue Eng Regen Med) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Wang et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Wei et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Wendler et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |
| Wu et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 8 |
| Yang et al. | Yes | Yes | No | Yes | Yes | Yes | Yes | No | 6 |
| Zhu et al. | Yes | No | No | Yes | Yes | Yes | Yes | Yes | 6 |
| Gao et al. | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | 7 |